Telix Pharmaceuticals Limited (TLX.AX)
| Previous close | 14.88 |
| Open | 14.94 |
| Bid | 14.80 x 993000 |
| Ask | 14.96 x 862200 |
| Day's range | 14.70 - 15.01 |
| 52-week range | 8.20 - 15.01 |
| Volume | |
| Avg. volume | 1,194,495 |
| Market cap | 4.927B |
| Beta (5Y monthly) | 2.35 |
| PE ratio (TTM) | 745.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Q1 2024 Revenue and Business Update
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M), an increase of 18% on the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s prostate cancer imaging product Illuc
- GlobeNewswire
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”). On
- PR Newswire
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation[1] for the Company's investigational glioma imaging product, TLX101-CDx (Pixclara™[2], 18F-floretyrosine or 18F-FET).
